Reported Late Thursday Feb 9, BriaCell Therapeutics Corp. Announces Results Of Shareholder Meeting; Approval Of The Company's New Omnibus Equity Incentive Plan
Author: Happy Mohamed | February 10, 2023 01:28am
BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW))))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, is pleased to announce the results of its annual general and special meeting of shareholders of the Company (the "Shareholders") for the year ended July 31, 2022 held on February 9, 2023 (the "Meeting"). A total of 6,663,370 common shares of the Company (the "Common Shares") were voted, representing 42.94% of the Company's issued and outstanding Common Shares. At the Meeting, the Shareholders overwhelmingly voted in favour of all proposed resolutions that consisted of the following:
- Appointment of MNP LLP as auditors of the Company for the ensuing year and authorizing the directors to fix their remuneration;
- Election of Dr. William V. Williams, Mr. Jamieson Bondarenko, Mr. Marc Lustig, Dr. Jane A. Gross, Dr. Rebecca Taub, Mr. Vaughn C. Embro-Pantalony, and Mr. Martin E. Schmieg as directors of the Company;
- Approval of the Company's new omnibus equity incentive plan (the "Omnibus Plan");
- Ratification of restricted share units awarded under the Omnibus Plan; and
- Approval and adoption of an amendment to the Articles of the Company to require the presence, in person or by proxy, of two or more shareholders representing at least 33 1/3% of the outstanding shares entitled to be voted in order to constitute a quorum at any meeting of shareholders, and to remove the quorum exception for succeeding meetings of shareholders.
Having received Shareholder approval, the Company's Omnibus Plan remains subject to final approval from the Toronto Stock Exchange. The formal report on voting results with respect to all matters voted upon during the Meeting will be filed on the Company's SEDAR profile at www.sedar.com.
Posted In: BCTX TSX:BCT